Showing 5871-5880 of 6035 results for "".
- SightLife Women Advocates Head to Nepal to Support Blindness Prevention Programhttps://modernod.com/news/sightlife-women-advocates-head-to-nepal-to-support-blindness-prevention-program/2479891/SightLife operates an innovative program in rural Nepal that is successfully preventing more than 125 cases of blindness each month, according to a company news release. In October, a group of women leaders in ophthalmology from around the US will visit Nepal to meet with health workers, p
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l
- Alcon Adds New Ultraviolet-Absorbing Only IOL Options to its AcrySof Portfoliohttps://modernod.com/news/alcon-adds-new-ultraviolet-absorbing-only-iol-options-to-its-acrysof-portfolio/2479895/Alcon expanded its AcrySof IOL portfolio with the introduction of multifocal and multifocal toric ultraviolet (UV)-absorbing IOLs, as well as the introduction of the AcrySof UV-Absorbing monofocal IOL with the UltraSert Preloaded Delivery System. “At Alcon, input from our surgeons is at th
- Oculus Announces Release of Smartfield Smart Compact Perimeterhttps://modernod.com/news/oculus-announces-release-of-smartfield-smart-compact-perimeter/2479897/Oculus has announced the release of its Smartfield perimeter, expanding its portfolio of compact visual field testing devices. The new Smartfield has been optimized specifically for examinations for functional impairment of the central visual field, but is also suited for peripheral measurements.
- Apellis Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophyhttps://modernod.com/news/apellis-announces-first-patient-dosed-in-its-phase-3-clinical-program-for-apl-2-in-patients-with-geographic-atrophy/2479898/Apellis Pharmaceuticals announced that it has commenced its phase 3 clinical program for APL-2 in patients with geographic atrophy (GA), consisting of two phase 3 trials (DERBY & OAKS.) The first patient has been dosed in the OAKS trial and the first patient has been enrolled in the
- New Joystick for the Keratograph 5M With Release Functionhttps://modernod.com/news/new-joystick-for-the-keratograph-5m-with-release-function/2479900/The Oculus Keratograph 5M now comes equipped with a new joystick, which includes a release function. The new feature enables the user to capture images and video sequences with the push of a button on the device. No need any more to switch to the mouse – the user’s hand stays resting on the new
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- Adolescents With Strabismus More Likely to Have Psychological Problemshttps://modernod.com/news/adolescents-with-strabismus-more-likely-to-have-psychological-problems/2479912/Adolescents with visible eye deviation due to strabismus may be prone to psychological problems, researchers in Turkey report. “The visible eye deviation caused by strabismus was a strong indicator of psychological distress in
- Dompé Receives FDA Approval of Oxervate, the First Drug for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/The FDA has approved the first drug to treat neurotrophic keratitis, a rare and progressive eye disease that can lead to corneal scarring and vision loss. Oxervate (cenegermin-bkbj ophthalmic solution), which is manufactured by Italian pharmaceutical company Dompé, is based on cenegermin-b
- FDA Approves First Drug for Neurotrophic Keratitishttps://modernod.com/news/fda-approves-first-drug-for-neurotrophic-keratitis/2479917/The FDA approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea. “While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating,” Wiley Chamber